AHA Scientific Sessions 2024 Late-Breaking and Featured Science Collection

Published: 29 October 2024

  • Views:

    Views Icon 2108

  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

Keep up-to-date with our video collection covering the American Heart Association's 2024 Scientific Sessions in Chicago. For expert insights on the hottest late-breaking and featured science trials, tune in to our collection.

  • To catch reviews on the most awaited trials, watch our recurring series View From the ThoraxCenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL).
  • Watch out for the Late-Breaker Discussions with Dr Harriette Van Spall for key clinical trial data and its implications for future research.
  • Our concise Expert Interviews provide key data, study designs and take-home messages from select faculty.
  • Don't miss the key take aways from our Highlights series.

More from this programme

Part 1

View From the Thoraxcenter

1 session
View from the Thoraxcenter: AHA 24 Late-breaking Preview Watch now

Part 2

Late-Breaker Discussions with Dr Harriette Van Spall

5 sessions
ZODIAC: Decision Support System to Aid Optimization of Early Lipid Lowering Therapies After ACS Watch now
NUDGE-FLU: Electronic Nudges to Increase Influenza Vaccination in Patients with MI Watch now
SUMMIT: Tirzepatide in Patients with HFpEF and Obesity Watch now
FLOW: Benefits of Semaglutide on CKD by Cardiovascular Status or Risk Watch now
REALIZE-K: Efficacy and Safety of SZC in Patients with HFrEF Receiving Spironolactone Watch now

Part 3

Expert Interviews

14 sessions
LIBerate-OLE: Long-Term Efficacy of Lerodalcibep in Patients at High Risk for CVD Watch now
LIBerate-HeFH_OLE: Lerodalcibep in Heterozygous Familial Hypercholesterolemia Watch now
Mavacamten: Real-World Experience from 22 Months of the REMS Program Watch now
VALOR-HCM: Mavacamten in Patients with Obstructive HCM Referred for Septal Reduction Therapy Watch now
EMPEROR-Preserved: Diastolic Dysfunction and Empagliflozin in Heart Failure Watch now
Amulet IDE: The AMPLATZER Amulet Left Atrial Appendage Occluder Five-Year Results Watch now
NTLA-2001 in Patients with Transthyretin Amyloidosis with Cardiomyopathy Watch now
SELECT: Semaglutide in Obese and Overweight Patients with a History of Coronary Artery Bypass Surgery Watch now
ENDEAVOR: Myeloperoxidase Inhibition with Mitiperstat in HFpEF Watch now
New Insights from CLEAR OUTCOMES: Bempedoic Acid in Statin-Intolerant Patients with PAD Watch now
ALPACAR: Phase 2 Trial of Zerlasiran in High Risk Patients Watch now
BROOKLYN: Safety and Efficacy of Obicetrapib in Patients with HeFH Watch now
KRAKEN: Phase 2 Trial of Muvalaplin in High Risk Patients Watch now
OPTION: LAA Closure with Oral Anticoagulation after AF Ablation Watch now

Part 4

Highlights

1 session
3 Trials That Will Change My Practice with Dr Michelle Kittleson Watch now

About the episode

AHA Conference 2024 -  BROOKLYN: Safety and efficacy outcomes of obicetrapib (NewAmsterdam Pharma) alongside lipid-lowering therapy in Heterozygous Familial Hypercholesterolemia (HeFH) management.

 

Dr Stephen Nicholls (Monash University and The Victorian Heart Hospital, Melbourne, AU) joins us onsite at AHA Conference to discuss the findings from BROOKLYN (NCT05425745).

 

BROOKLYN is a phase 3, randomized, placebo-controlled trial investigating the use of obicetrapib in patients with HeFH who have undergone at least eight weeks of maximally tolerated lipid modifying therapy prior to screening. 354 patients were enrolled in the trial and were followed-up after the 365-day treatment period. The primary outcome measure was the percent change from baseline to day 84 in low density lipoprotein-cholesterol.

 

Interview Questions:
1.    What is the reasoning behind the trial and the current unmet needs in HeFH management?
2.    Could you tell us about the mechanism of action behind obicetrapib?
3.    What was the study design and patient population?
4.    What were the key findings?
5.    What further research is needed in this area?

 

Recorded on-site at AHA Conference in Chicago, 2024.

Editors: Yazmin Sadik, Jordan Rance.
Videographers: Mike Knight, Dan Brent, Oliver Miles, Tom Green, David Ben-Harosh.

Support: This is an independent interview produced by Radcliffe Cardiology.

Faculty Biographies

Stephen Nicholls

Stephen Nicholls

Monash Victorian Heart Institute Director and Professor of Cardiology

Prof Stephen Nicholls is the Director of the Monash Victorian Heart Institute in Melbourne, AU and a Professor of Cardiology at Monash University. He also serves as the Deputy Director and Heart Health Theme Leader at the South Australian Health and Medical Research Institute, Adelaide, AU.

Prof Nicholls completed his cardiology training at the John Hunter Hospital and received his Doctor of Philosophy (PhD) in Medical Biochemistry from the University of Adelaide.

He has written over 770 manuscripts, book chapters and conference proceedings. His research is focused on strategies to reduce the risk of heart disease, novel vascular imaging and generating an understanding of the factors that promote plaque formation. He has raised over $100 million in research funding and has received multiple awards, including the Cleveland Clinic Innovator Award in 2011, the NHMRC Research Excellence Award in 2016, the RT Hall Price in 2018 and the Eric Susman Prize in…

View full profile

Comments

You must be to comment. If you are not registered, you can register here.